

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60663	APPLICATION NO. 10/597,154
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Baldwin et al.	
		FILING DATE July 13, 2006	GROUP 1625

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US 4,775,761	01 Oct 88	Strupczewski			
	US 5,256,673	26 Oct 93	Böttcher et al.			
	US 6,245,799	12 Jun 01	Asselin et al.			
	US2002/0161004	31 Oct 02	Browner et al.			
	US2002/147189	10 Oct 02	Cai et al.			
	US2003/0022898	30 Jan 03	Burke et al.			
	USSN 11/570,060	05 Dec 06	Jeffrey K. Kerns			
	USSN 11/575,416	16 Mar 07	Kerns et al.			
	USSN 11/931,189	31 Oct 07	Deng et al.			
	USSN 12/532,773	20 Mar 08	Jeffrey K. Kerns			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	DE3342632	05 Jun 85	Germany				
	DE19500689	18 Jul 96	Germany				
	DE19807993	02 Sep 99	Germany				
	DE19928424	28 Dec 00	Germany				
	DE10112151	19 Sep 02	Germany				
	DE10259244	01 Jul 04	Germany				
	EP279263	04 Aug 93	EP				
	EP610134	10 Aug 94	EP				
	EP416609	08 Jan 97	EP				
	EP0812826	17 Dec 97	EP				
	EP1077213	21 Feb 01	EP				

EXAMINER

•**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60663	APPLICATION NO. 10/597,154
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Baldwin et al.	
		FILING DATE July 13, 2006	GROUP 1625

		EP1134221	19 Sep 01	EP				
		EP1209158	29 May 02	EP				
		WO199421627	29 Sep 94	PCT				
		WO199917773	15 Apr 99	PCT				
		WO2001000610	04 Jan 01	PCT				
		WO2001030774	03 May 01	PCT				
		WO200134598	17 May 01	PCT				
		WO2001058890	16 Aug 01	PCT				
		WO2001068648	20 Sept 01	PCT				
		WO2001083472	08 Nov 01	PCT				
		WO200187298	22 Nov 01	PCT				
		WO200198290	27 Dec 01	PCT				
		WO200214317	21 Feb 02	PCT				
		WO2002016353	28 Feb 02	PCT				
		WO2002024679	28 Mar 02	PCT				
		WO2002024693	28 Mar 02	PCT				
		WO2002028860	28 Mar 02	PCT				
		WO2002030353	18 Apr 02	PCT				
		WO200230423	18 Apr 02	PCT				
		WO2002041843	30 May 02	PCT				
		WO2002044153	06 June 02	PCT				
		WO2002046171	13 June 02	PCT				
		WO200251837	04 July 02	PCT				
		WO2002060386	08 Aug 02	PCT				
		WO2002094322	28 Nov 02	PCT				
		WO2002094813	28 Nov 02	PCT				

EXAMINER

·**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60663	APPLICATION NO. 10/597,154
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Baldwin et al.	
		FILING DATE July 13, 2006	GROUP 1625

		WO200294265	28 Nov 02	PCT				
		WO2003010158	06 Feb 03	PCT				
		WO2003010163	06 Feb 03	PCT				
		WO2003022898	20 Mar 03	PCT				
		WO2003024935	27 Mar 03	PCT				
		WO2003024936	27 Mar 03	PCT				
		WO2003027075	03 Apr 03	PCT				
		WO2003035625	01 May 03	PCT				
		WO200307076	23 Jan 03	PCT				
		WO2003084959	16 Oct 03	PCT				
		WO2003095430	20 Nov 03	PCT				
		WO2003103661	18 Dec 03	PCT				
		WO2004019935	11 Mar 04	PCT				
		WO2004022553	18 Mar 04	PCT				
		WO2004024730	25 Mar 04	PCT				
		WO2004024732	25 Mar 04	PCT				
		WO2004024736	25 Mar 04	PCT				
		WO2004075846	10 Sept 04	PCT				
		WO2004089913	21 Oct 04	PCT				
		WO2004106293	09 Dec 04	PCT				
		WO2005012283	10 Feb 05	PCT				
		WO2005035527	21 Apr 05	PCT				
		WO2005035537	21 Apr 05	PCT				
		WO2005067923	28 July 05	PCT				
		WO2006002434	05 Jan 06	PCT				
		WO 2006/034317	30 Mar 06	PCT				

EXAMINER

·**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60663	APPLICATION NO. 10/597,154
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Baldwin et al.	
		FILING DATE July 13, 2006	GROUP 1625

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Aupperle et al. , "NF- κ B Regulation by I κ B Kinase in Primary Fibroblast-Like Synoviocytes" J. Immunology (1999) 163:427-433.
	Aupperle et al. , "NF- κ B Regulation by I κ B Kinase-2 in Rheumatoid Arthritis Synoviocytes" J. Immunology (2001) 166:31496-31501
	Breton et al. , "The Natural Product Hymenialdisine Inhibits Interleukin-8 Production in U937 Cells by Inhibition of Nuclear Factor- κ B" JPET (1997) 282(1):459-466.
	Burke et al. , "BMS-345541 Is a Highly Selective Inhibitor of I κ B Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF- κ B-dependent Transcription in Mice" J. Biol Chem. (2003) 278:1450-1456.
	Guttridge et al. , "NF- κ B-Induced Loss of MyoD Messenger RNA: Possible Role in Muscle Decay and Cachexia " Science (2000) 289:2363-2365.
	Murata et al. , , "Discovery of novel and selective IKK- β serine-threonine protein kinase inhibitors. Part 1." Bioorg. Med. Chem. Letter (2003) 13:913-198.
	Murata et al. , "Synthesis and structure-activity relationships of novel IKK- β inhibitors. Part 2: Improvement of in vitro activity" Bioorg. Med. Chem. Letter (2004) 14(15):4013-4017 and "Synthesis and structure-activity relationships of novel IKK- β inhibitors. Part 3: Orally active anti-inflammatory agents," Bioorg. Med. Chem. Letter (2004) 14(15):4019-4022.
	Peet et al. , "I κ B Kinases α and β Show a Random Sequential Kinetic Mechanism and Are Inhibited by Staurosporine and Quercetin" J. Biol. Chem. (1999) 274:32655-32661.
	Pierce, et al. , "Novel Inhibitors of Cytokine-induced I κ B α Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects <i>in Vivo</i> " J. Biol. Chem. (1997) 272:21096-21103.
	Roshak, et al. , "Inhibition of NF κ B-Mediated Interleukin-1 β -Stimulated Prostaglandin E ₂ Formation by the Marine Natural Product Hymenialdisine" JPET (1997) 283(2):955-961.
	Roshak, et al. , "Manipulation of Distinct NF κ B Proteins Alters Interleukin-1 β -induced Human Rheumatoid Synovial Fibroblast Prostaglandin E ₂ Formation" J. Biol. Chem. (1996) 271:31496-31501.
	Sullivan et al. , "2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'-bis(trifluoromethyl)phenyl)-carboxamide: A Potent Inhibitor of NF- κ B- and AP-1-Mediated Gene Expression Identified Using Solution-Phase Combinatorial Chemistry" J. Med. Chem. (1998) 41:413-419.

EXAMINER

·**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60663	APPLICATION NO. 10/597,154
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Baldwin et al.	
		FILING DATE July 13, 2006	GROUP 1625

		Tak et al., "Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation" <i>Arthritis and Rheumatism</i> (2001) 44(8):1897-1907.
		Wahl et al., "Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B" <i>J. Clin. Invest.</i>(1998) 101(5):1163-1174.
		Wisniewski et al., "Assay for IκB Kinases Using an <i>in Vivo</i> Biotinylated IκB Protein Substrate" <i>Analytical Biochem.</i> (1999) 274:220-228
		Abstract No. 98323-88-7 (29 Sept 1985)

EXAMINER	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	